In a significant move for the psychedelic industry, ACS Laboratory, celebrated as the largest hemp and cannabis testing facility in the Eastern U.S., has unveiled a comprehensive Amanita mushroom testing programme.
Located in Boca Raton, Florida, this initiative comes as Amanita mushrooms are increasingly recognised for their distinct psychoactive properties.
These mushrooms, noted for their unique effects and unchecked constituents, require rigorous testing to ascertain potency, purity, and especially to confirm the absence of components like psilocybin and psilocin.
ACS Laboratory, having earned the coveted DEA licence, is ideally positioned to provide such robust and precise assessments.
The expansive testing framework has evolved in 2023, incorporating mushroom and Kratom analyses alongside its established cannabis and hemp expertise.
The DEA licensing proves pivotal here, ensuring meticulous checks against potentially illegal compounds.
Roger Brown, the president of ACS Laboratory, emphasised the significance of delivering precise results to the flourishing Amanita industry.
He stated, “Our state-of-the-art facility and advanced methodologies enable us to deliver accurate and clinical-grade results, reinforcing our commitment to excellence and accountability.”
To further its commitment to transparency, the laboratory introduces a Certificate of Analysis (COA) for each specimen, accessible via a public portal.
Moreover, incorporating QR codes on product packaging linked to COAs and harnessing blockchain for tamper-proofing, ACS Laboratory accentuates its drive to establish unwavering consumer trust and combat fraud.
While Amanita mushrooms attract attention for their potential therapeutic benefits, ACS Laboratory is proving indispensable for brands keen on maintaining product excellence, compliance, and safety.
Notably, with a reputation cemented by 82 Emerald Test Badges, ACS Laboratory’s dedication to precise results, innovation, and transparency remains unmatched in the psychedelic space.